Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study.


Journal

The Lancet. Respiratory medicine
ISSN: 2213-2619
Titre abrégé: Lancet Respir Med
Pays: England
ID NLM: 101605555

Informations de publication

Date de publication:
02 2020
Historique:
received: 11 07 2019
revised: 05 08 2019
accepted: 07 08 2019
pubmed: 4 10 2019
medline: 25 8 2020
entrez: 4 10 2019
Statut: ppublish

Résumé

Transbronchial lung cryobiopsy (TBLC) is a novel technique for sampling lung tissue for interstitial lung disease diagnosis. The aim of this study was to establish the diagnostic accuracy of TBLC compared with surgical lung biopsy (SLB), in the context of increasing use of TBLC in clinical practice as a less invasive biopsy technique. COLDICE was a prospective, multicentre, diagnostic accuracy study investigating diagnostic agreement between TBLC and SLB, across nine Australian tertiary hospitals. Patients with interstitial lung disease aged between 18 and 80 years were eligible for inclusion if they required histopathological evaluation to aid diagnosis, after detailed baseline evaluation. After screening at a centralised multidisciplinary discussion (MDD), patients with interstitial lung disease referred for lung biopsy underwent sequential TBLC and SLB under one anaesthetic. Each tissue sample was assigned a number between 1 and 130, allocated in a computer-generated random sequence. Encoded biopsy samples were then analysed by masked pathologists. At subsequent MDD, de-identified cases were discussed twice with either TBLC or SLB along with clinical and radiological data, in random non-consecutive order. Co-primary endpoints were agreement of histopathological features in TBLC and SLB for patterns of definite or probable usual interstitial pneumonia, indeterminate for usual interstitial pneumonia, and alternative diagnosis; and for agreement of consensus clinical diagnosis using TBLC and SLB at MDD. Concordance and κ values were calculated for each primary endpoint. This study is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12615000718549. Between March 15, 2016, and April 15, 2019, we enrolled 65 patients (31 [48%] men, 34 [52%] women; mean age 66·1 years [SD 9·3]; forced vital capacity 83·7% [SD 14·2]; diffusing capacity for carbon monoxide 63·4% [SD 12·8]). TBLC (7·1 mm, SD 1·9) and SLB (46·5 mm, 14·9) samples were each taken from two separate ipsilateral lobes. Histopathological agreement between TBLC and SLB was 70·8% (weighted κ 0·70, 95% CI 0·55-0·86); diagnostic agreement at MDD was 76·9% (κ 0·62, 0·47-0·78). For TBLC with high or definite diagnostic confidence at MDD (39 [60%] of 65 cases), 37 (95%) were concordant with SLB diagnoses. In the 26 (40%) of 65 cases with low-confidence or unclassifiable TBLC diagnoses, SLB reclassified six (23%) to alternative high-confidence or definite MDD diagnoses. Mild-moderate airway bleeding occurred in 14 (22%) patients due to TBLC. The 90-day mortality was 2% (one of 65 patients), following acute exacerbation of idiopathic pulmonary fibrosis. High levels of agreement between TBLC and SLB for both histopathological interpretation and MDD diagnoses were shown. The TBLC MDD diagnoses made with high confidence were particularly reliable, showing excellent concordance with SLB MDD diagnoses. These data support the clinical utility of TBLC in interstitial lung disease diagnostic algorithms. Further studies investigating the safety profile of TBLC are needed. University of Sydney, Hunter Medical Research Institute, Erbe Elektromedizin, Medtronic, Cook Medical, Rymed, Karl-Storz, Zeiss, and Olympus.

Sections du résumé

BACKGROUND
Transbronchial lung cryobiopsy (TBLC) is a novel technique for sampling lung tissue for interstitial lung disease diagnosis. The aim of this study was to establish the diagnostic accuracy of TBLC compared with surgical lung biopsy (SLB), in the context of increasing use of TBLC in clinical practice as a less invasive biopsy technique.
METHODS
COLDICE was a prospective, multicentre, diagnostic accuracy study investigating diagnostic agreement between TBLC and SLB, across nine Australian tertiary hospitals. Patients with interstitial lung disease aged between 18 and 80 years were eligible for inclusion if they required histopathological evaluation to aid diagnosis, after detailed baseline evaluation. After screening at a centralised multidisciplinary discussion (MDD), patients with interstitial lung disease referred for lung biopsy underwent sequential TBLC and SLB under one anaesthetic. Each tissue sample was assigned a number between 1 and 130, allocated in a computer-generated random sequence. Encoded biopsy samples were then analysed by masked pathologists. At subsequent MDD, de-identified cases were discussed twice with either TBLC or SLB along with clinical and radiological data, in random non-consecutive order. Co-primary endpoints were agreement of histopathological features in TBLC and SLB for patterns of definite or probable usual interstitial pneumonia, indeterminate for usual interstitial pneumonia, and alternative diagnosis; and for agreement of consensus clinical diagnosis using TBLC and SLB at MDD. Concordance and κ values were calculated for each primary endpoint. This study is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12615000718549.
FINDINGS
Between March 15, 2016, and April 15, 2019, we enrolled 65 patients (31 [48%] men, 34 [52%] women; mean age 66·1 years [SD 9·3]; forced vital capacity 83·7% [SD 14·2]; diffusing capacity for carbon monoxide 63·4% [SD 12·8]). TBLC (7·1 mm, SD 1·9) and SLB (46·5 mm, 14·9) samples were each taken from two separate ipsilateral lobes. Histopathological agreement between TBLC and SLB was 70·8% (weighted κ 0·70, 95% CI 0·55-0·86); diagnostic agreement at MDD was 76·9% (κ 0·62, 0·47-0·78). For TBLC with high or definite diagnostic confidence at MDD (39 [60%] of 65 cases), 37 (95%) were concordant with SLB diagnoses. In the 26 (40%) of 65 cases with low-confidence or unclassifiable TBLC diagnoses, SLB reclassified six (23%) to alternative high-confidence or definite MDD diagnoses. Mild-moderate airway bleeding occurred in 14 (22%) patients due to TBLC. The 90-day mortality was 2% (one of 65 patients), following acute exacerbation of idiopathic pulmonary fibrosis.
INTERPRETATION
High levels of agreement between TBLC and SLB for both histopathological interpretation and MDD diagnoses were shown. The TBLC MDD diagnoses made with high confidence were particularly reliable, showing excellent concordance with SLB MDD diagnoses. These data support the clinical utility of TBLC in interstitial lung disease diagnostic algorithms. Further studies investigating the safety profile of TBLC are needed.
FUNDING
University of Sydney, Hunter Medical Research Institute, Erbe Elektromedizin, Medtronic, Cook Medical, Rymed, Karl-Storz, Zeiss, and Olympus.

Identifiants

pubmed: 31578168
pii: S2213-2600(19)30342-X
doi: 10.1016/S2213-2600(19)30342-X
pii:
doi:

Banques de données

ANZCTR
['ACTRN12615000718549']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

171-181

Investigateurs

David Arnold (D)
Christopher Cao (C)
Amy Cashmore (A)
Shannon Cleary (S)
Tiffany-Jane Evans (TJ)
Bruce French (B)
Monika Geis (M)
Laura Glenn (L)
Michael Hibbert (M)
Alvin Ing (A)
Allen James (A)
Graham Meredith (G)
Christopher Merry (C)
Anand Pudipeddi (A)
Tajalli Saghaie (T)
Rajesh Thomas (R)
Claire Thomson (C)
Scott Twaddell (S)

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Lauren K Troy (LK)

Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia. Electronic address: ltroy@med.usyd.edu.au.

Christopher Grainge (C)

John Hunter Hospital, New Lambton Heights, NSW, Australia; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.

Tamera J Corte (TJ)

Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

Jonathan P Williamson (JP)

Liverpool Hospital, Liverpool, NSW, Australia; Macquarie University Hospital, Sydney, NSW, Australia.

Michael P Vallely (MP)

Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Macquarie University Hospital, Sydney, NSW, Australia.

Wendy A Cooper (WA)

Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

Annabelle Mahar (A)

Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

Jeffrey L Myers (JL)

Michigan Medicine, University of Michigan, Ann Arbour, MI, USA.

Simon Lai (S)

Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

Ellie Mulyadi (E)

Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

Paul J Torzillo (PJ)

Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

Martin J Phillips (MJ)

Macquarie University Hospital, Sydney, NSW, Australia; Sir Charles Gairdner Hospital, Nedlands, WA, Australia.

Helen E Jo (HE)

Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

Susanne E Webster (SE)

Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

Qi T Lin (QT)

Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

Jessica E Rhodes (JE)

Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

Matthew Salamonsen (M)

Fiona Stanley Hospital, Murdoch, WA, Australia.

Jeremy P Wrobel (JP)

Fiona Stanley Hospital, Murdoch, WA, Australia; University of Notre Dame Australia, Fremantle, WA, Australia.

Benjamin Harris (B)

Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Artarmon, NSW, Australia.

Garrick Don (G)

Royal North Shore Hospital, Artarmon, NSW, Australia.

Peter J C Wu (PJC)

Westmead Hospital, Westmead, NSW, Australia.

Benjamin J Ng (BJ)

Nepean Hospital, Kingswood, NSW, Australia.

Christopher Oldmeadow (C)

Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.

Ganesh Raghu (G)

University of Washington, Seattle, WA, USA.

Edmund M T Lau (EMT)

Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH